Efficacy Analysis Of Bevacizumab Combined With Chemotherapy In Lung Metastasis Of Colorectal Cancer

Objective: This paper should provide a reference for the study of the efficacy of bevacizumab combined with chemotherapy in the treatment of Colorectalcancer(CRC)patients with lung metastasis,and for the selection of treatment options for CRC patients with lung metastasisMethods: Collected in August 2014-January 2022 in qinghai university affiliated hospital and qinghai province Red Cross hospital diagnosed with lung metastasis after colorectal cancer line will contain beacizumab bead bead sheet resistance,cetuximab treatment and current guidelines recommend treatment of colorectal cancer patients with chemotherapy alone,and case data complete accord with the standard set of a total of 101 cases as the research object,The efficacy of these three different treatment regiments in the treatment of CRC lung metastasis was compared to explore the effect of bevacizumab combined with chemotherapy in the treatment of CRC lung metastasis.Collect basic information about cases.The data was input by EXCEL software and then analyzed by SPSS25.0 software.The project analysis included: Quantitative data analysis,counting data analysis,pinpair analysis between groups,component before and after analysis,multifactor ordered logistic regression analysis,survival curve drawing,etc.,and statistical methods were used to analyze and determine whether there was statistical significance,P < 0.05 was statistically significant.Results: Overall baseline characteristics(gender(P =0.969),age(P=0.149),lesion size(P =0.104),cycle(P =0.131),efficacy(P =0.892),operation(P =0.450))were not statistically significant.Bevacizumab combined with chemotherapy had a certain advantage in second-line treatment of mPFS(bevacizumab: 6.00(95%CI 3.42-8.58)months,cetuximab: 4.33(95%CI 3.60-5.08)months,while chemotherapy alone: 3.00(95%CI1.98-4.02)months),the difference was statistically significant(P=0.007);Among patients who underwent surgery,the treatment regimen with bevacizumab(mPFS6.00(95%CI3.84-8.16)months)was superior to the other two groups(cetuximab with mPFS3.00(95%CI 1.84-4.17)months,and chemotherapy alone: MPFS4.50(95%ci 2.61-6.39)months),the difference was statistically significant among the three groups(p=0.007).In terms of the lesion site,The cetuximab group(3.83(95%CI 3.13-4.52)months of mPFS and chemotherapy alone(3.00(95%CI 2.27-3.73)months of mPFS)were less effective than the bevacizumab group(6.75(95%CI)mPFS)3.62-9.88)months),the difference was statistically significant(p=0.003)Conclusion: Bevacizumab and cetuximab combined with chemotherapy showed a significant advantage in the treatment of lung metastasis of CRC in the three treatment regiments including bevacizumab,cetuximab and chemotherapy alone.Primary tumor site,prior surgery,and second-line treatment were the factors affecting mPFS,while age,gender,and lesion size did not.Patients with lung metastases who have undergone colon cancer surgery are more likely to achieve better clinical outcomes with bevacizumab.On second-line treatment,bevacizumab had longer mPFS than cetuximab.